Results 211 to 220 of about 228,118 (255)

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager. [PDF]

Front Immunol
Wang H, Zhao R, Liu M, Jiang T, Sun D, Chi L, Huang Y, Lu Z, Yun Y, Wang X.   +9 more
europepmc   +1 more source

Autoimmunity and Periodontitis

Journal of Periodontal Research, EarlyView.
In a microbe‐driven inflammatory environment, peptidyl‐arginine deiminase (PAD) enzymes from neutrophils and Porphyromonas gingivalis citrullinate both microbial and self‐antigens. B cell presentation of citrullinated or self‐mimicking epitopes activates T cells that assist B cells in antibody isotype switching, affinity maturation, epitope spreading ...
Massimo Costalonga, Vivek Thumbigere‐Math, Mark C. Herzberg   +2 more
wiley   +1 more source

A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens. [PDF]

Front Immunol
Guo L, Xie H, Yin D, Zhu G, Zhai P, Pei G, Zhang W, Xiao F, Lyu J, Tang D.   +9 more
europepmc   +1 more source

Inflammation and mechanical force‐induced bone remodeling

Periodontology 2000, EarlyView.
Abstract Periodontitis arises from imbalanced host–microbe interactions, leading to dysbiosis and destructive inflammation. The host's innate and adaptive immune responses produce pro‐inflammatory mediators that stimulate destructive events, which cause loss of alveolar bone and connective tissue attachment.
Hyeran Helen Jeon, Xin Huang, Leticia Rojas Cortez, Puttipong Sripinun, Jung‐me Lee, Julie J. Hong, Dana T. Graves   +6 more
wiley   +1 more source

A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma. [PDF]

Med Sci Monit
Lv X, Chen X, Ge Y, Si G, Li Y, Li X, Yuan X.   +6 more
europepmc   +1 more source

Antibiotic‐mediated immune modulation in periodontitis

Periodontology 2000, EarlyView.
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez, R. M. Arce, Camila Pinheiro Furquim, Cristiane Gonçalves, Alpdogan Kantarci, Magda Feres, Nidia C. Castro dos Santos   +6 more
wiley   +1 more source

Genetic Determinants of Autoimmune Myocarditis: From Candidate Genes to GWAS Insights. [PDF]

Genes (Basel)
Pirzadah H, Ibrahim Z, Pirzadah Y, Yusuf N.   +3 more
europepmc   +1 more source

Clinical Impact of CTLA4 and LAG3 Single‐Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T‐Cell Therapy

Hematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy targeting B‐cell maturation antigen (BCMA) is a highly effective treatment option for patients with relapsed refractory multiple myeloma (RRMM). However, reliable biomarkers predicting long‐term treatment response remain elusive. Germline single‐nucleotide polymorphisms (SNPs) in immune checkpoint
Elisa Suter, Martina Bertschinger, Inna Shaforostova, Marie‐Noelle Kronig, Henning Nilius, Ulrike Bacher, Katja Seipel, Thomas Pabst   +7 more
wiley   +1 more source

Advances in CAR-T Cell Therapy: From Structural Design Innovations to Clinical Translation Challenges. [PDF]

J Cancer
Gao H, Fang Y, Zhang P, Qian Q.
europepmc   +1 more source